Enteris Biopharma Inc., of Boonton, N.J., said the first woman has been dosed in its phase IIa trial to evaluate Ovarest, an oral formulation of leuprolide, which binds to the gonadotropin releasing hormone receptor, for the treatment of endometriosis.